The FDA's usual end-of-year flurry of regulatory approvals is a little lighter than usual, but the agency has delivered some ...

One of the pioneers in AI-powered drug discovery, Insilico Medicine, has completed an initial public offering (IPO) in Hong ...

Equip health professionals with resources to diagnose and treat conditions across all skin tones. Make mental health support ...

Shares in Ultragenyx and Mereo BioPharma have plunged after their drug for osteogenesis imperfecta (OI) or brittle bone ...

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Andrew Newland, CEO of ANGLE, about why live cell liquid ...

The NHS has an extraordinary opportunity in 2026. Unified data, decision intelligence, and strong workforce capability can ...

Judge Lance Walker sided with the American Hospital Association (AHA) and other plaintiffs in the lawsuit, brought in a Maine ...

In 2026, we will see widespread adoption of AI tools that automate time-consuming administrative tasks: drafting clinical ...

Sanofi's last job before breaking up for the Christmas holiday? Putting the finishing touches on a $2.5 billion agreement to buy vaccine developer Dynavax. The French pharma major has started a $15.50 ...

A pioneering clinical trial backed by the EU and drugmaker Takeda will look for biomarkers that could be used to identify people at risk of developing Crohn's disease in the hope of intervening early ...

Novartis is one of the world's top pharmaceutical companies, and along with neighbours Roche, the mainstay of Switzerland's centuries-long contribution to new medicines. Headquartered in Basel, ...

Bayer has abandoned development of its investigational P2X3 receptor antagonist eliapixant, despite promising efficacy data in clinical trials, on what appears to be safety grounds. The decision comes ...